Cargando…
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
BACKGROUND: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown. METHODS: A retrospective, real‐world analysis was performed on the outcomes of 377 patients with resist...
Autores principales: | Alvarez‐Larrán, Alberto, Garrote, Marta, Ferrer‐Marín, Francisca, Pérez‐Encinas, Manuel, Mata‐Vazquez, M. Isabel, Bellosillo, Beatriz, Arellano‐Rodrigo, Eduardo, Gómez, Montse, García, Regina, García‐Gutiérrez, Valentín, Gasior, Mercedes, Cuevas, Beatriz, Angona, Anna, Gómez‐Casares, María Teresa, Martínez, Clara M., Magro, Elena, Ayala, Rosa, del Orbe‐Barreto, Rafael, Pérez‐López, Raúl, Fox, Maria Laura, Raya, José‐María, Guerrero, Lucía, García‐Hernández, Carmen, Caballero, Gonzalo, Murillo, Ilda, Xicoy, Blanca, Ramírez, M. José, Carreño‐Tarragona, Gonzalo, Hernández‐Boluda, Juan Carlos, Pereira, Arturo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324831/ https://www.ncbi.nlm.nih.gov/pubmed/35417564 http://dx.doi.org/10.1002/cncr.34195 |
Ejemplares similares
-
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2020) -
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
por: Triguero, Ana, et al.
Publicado: (2022) -
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023) -
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021) -
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2023)